Fixed-dose combination of sitagliptin and metformin for the treatment of type 2 diabetes
Jonathan K ReynoldsWashington State University, College of Pharmacy, Pullman, WA, USAAbstract: JanumetTM, a fixed dose combination of sitagliptin/metformin HCL manufactured by Merck Pharmaceuticals, has received US Food and Drug Administration approval for treatment of patients with type 2 diabetes,...
Saved in:
Main Author: | Jonathan K Reynolds |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2009
|
Subjects: | |
Online Access: | https://doaj.org/article/c03116aca28d4503b4a56a3c00a08e98 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Clinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes
by: Karen Barnard, et al.
Published: (2010) -
Clinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes
by: Green J, et al.
Published: (2010) -
Fixed-dose combinations in type 2 diabetes – role of the canagliflozin metformin combination
by: Fleming JW, et al.
Published: (2015) -
Patient considerations and clinical utility of a fixed dose combination of saxagliptin/metformin in the treatment of type 2 diabetes
by: Maffioli P, et al.
Published: (2011) -
Sitagliptin as combination therapy in the treatment of type 2 diabetes mellitus
by: Shannon A Miller, et al.
Published: (2009)